Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 82, Issue 6, Pages 1305-1313Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2020.02.009
Keywords
atopic dermatitis; burden of disease; itch; JAK inhibitor; Janus kinase; pruritus; quality of life; ruxolitinib; Skindex-16
Categories
Funding
- Incyte Corporation
Ask authors/readers for more resources
Background: Atopic dermatitis (AD), a chronic, highly pruritic skin disorder, impairs quality of life (QoL). Janus kinase inhibitors suppress inflammatory and pruritus-associated cytokine signaling in AD. Objective: To report the effects of ruxolitinib (RUX) cream on itch and QoL in AD. Methods: A total of 307 adult patients with an Investigator's Global Assessment (score of 2 or 3) and 3% to 20% affected body surface area were randomly assigned for 8 weeks to receive double-blind treatment with RUX (1.5% twice daily, 1.5% once daily, 0.5% once daily, or 0.15% once daily), vehicle twice daily, or triamcinolone cream (0.1% twice daily for 4 weeks then vehicle for 4 weeks). Itch was measured by using the numerical rating scale, and patient QoL was assessed with Skindex-16. Results: Improvements in itch numerical rating scale and Skindex-16 were observed with RUX cream. Overall, 42.5% of patients who applied 1.5% RUX twice daily experienced minimal clinically important difference in itch within 36 hours of treatment (vehicle, 13.6%; P < .01); near-maximal improvement was observed by week 4. Itch reduction was associated with improved QoL burden (Pearson correlation, 0.67; P < .001). Significant improvements in Skindex-16 overall scores were noted at week 2. Limitations: Facial AD lesions were not treated. Conclusion: RUX cream provides a clinically meaningful reduction in itch and QoL burden.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available